All news from R&D

ASD Reversed with Microbial-based Treatment in Mouse Models

An unconventional approach has successfully reversed deficits in social behaviors associated with autism spectrum disorders (ASD) in genetic, environmental and idiopathic mouse models of the condition. Researchers report in the journal  Neuron that administration of the bacterium Lactobacillus reuteri could lead to specific changes in the brain that social deficits through a reverse mechanism involve the vagus nerve That and the oxytocin-dopamine reward system. These findings hold hope for the development of novel therapies for neurological disorders by modulating specific microbes in the gut.

Nanocarrier-Delivered MicroRNA In Sepsis Treatment

One in three patients who die in the U.S. dies of sepsis, according to the Centers for Disease Control and Prevention. It is one of the leading causes of death in intensive care units and, with an estimated price tag of $20 billion in 2011, the most expensive condition that hospitals treat.

Loxosceles Bites: New Ointment is Tested on Humans

The bite from a brown recluse spider (Loxosceles) can cause skin necrosis, renal failure, and even death. A new ointment is being tested in Brazil, however. Its effects have already been proven in tests conducted in cell cultures and animal models. Now the ointment will have its immunomodulatory action tested on humans in Phase III clinical trials, and it may be included in the treatment protocol for patients who develop lesions caused by the spider bite.

Epidermal Electronics Development: Silk Adhesive Play a Role

Producing effective epidermal electronics requires a strong, biocompatible interface between a biological surface and a sensor. Here, to KAIST team employed calcium-modified silk fibroin as a biocompatible and strong adhesive. This technology led to the development of epidermal electronics with strong adhesion for patients who need drug injections and physiological monitoring over a long time.

Pediatric Post-marketing Drug Studies: Two-third Studies are Missing

The FDA requires clinical studies of new drugs in pediatric populations, since many drugs developed for use in adults are also used in children. These studies are often requested after the drug is approved in adults, as "post-marketing" trials. However, a study from Boston Children's Hospital finds that only a third of these mandatory trials were completed within an average of seven years. As a result, most new drug labels continue to lack information needed for use in children, and most FDA-approved medications remain untreated in children.

Cancer Research: New Virus Eqipped that Kills Carcinoma Cells with Protein

Scientists have equipped a virus that kills carcinoma cells with a protein that can also target and kill adjacent cells that are tricked into shielding cancer from the immune system. It is the first time that cancer-associated fibroblasts within solid tumors – healthy cells that have been tricked into protecting cancer from the immune system and supplying it with growth factors and nutrients – have been specifically targeted in this way.